| PSTV Stock | | | USD 1.29 0.01 0.78% |
CEO
MD MBA is CEO President of Plus Therapeutics
| Age | 61 |
| Address | 4200 Marathon Boulevard, Austin, TX, United States, 78756 |
| Phone | 737 255 7194 |
| Web | https://plustherapeutics.com |
Plus Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.6939) % which means that it has lost $0.6939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Equity is likely to climb to 10.37 in 2024, whereas
Return On Tangible Assets are likely to drop
(1.27) in 2024.
Total Current Assets is likely to climb to about 17.1
M in 2024, whereas
Total Assets are likely to drop slightly above 10.8
M in 2024.
Plus Therapeutics currently holds 4.18
M in liabilities with Debt to Equity
(D/E) ratio of 0.53, which is about average as compared to similar companies. Plus Therapeutics has a current ratio of 2.75, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Plus Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | CEO Age |
| FOCIS MD | Candel Therapeutics | 63 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Plus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. Plus Therapeutics (PSTV) is traded on NASDAQ Exchange in USA. It is located in 4200 Marathon Boulevard, Austin, TX, United States, 78756 and employs 20 people. Plus Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Plus Therapeutics Leadership Team
Elected by the shareholders, the Plus Therapeutics' board of directors comprises two types of representatives: Plus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Plus. The board's role is to monitor Plus Therapeutics' management team and ensure that shareholders' interests are well served. Plus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Plus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Plus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Plus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to
measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.